Jeffrey Hassall ANZBMS-MEPSA-ANZORS 2022

Abstracts this author is presenting:

• The proportion of patients who reach the BMD surrogate threshold effect on romosozumab: a post hoc analysis of the randomised FRAME and ARCH phase 3 trials — ANZBMS Abstracts